Trial reportJournal of the American College of Cardiology2014
Extent of coronary and myocardial disease and benefit from surgical revascularization in ischemic LV dysfunction [Corrected].
Trial report in Journal of the American College of Cardiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00023595 (Surgical Treatment for Ischemic Heart Failure), which is not on this map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Surgical Treatment for Ischemic Heart Failure (STICH)
Who cites it
45 citing papers in PubMed, 111 citations in OpenAlex.
- Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial.Circulation · 2022Trial
- Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy.The New England journal of medicine · 2019Trial
- Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy.European journal of heart failure · 2019Trial
- Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy.The New England journal of medicine · 2016Trial
- Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH.Journal of the American College of Cardiology · 2015Trial
- Severity of Remodeling, Myocardial Viability, and Survival in Ischemic LV Dysfunction After Surgical Revascularization.JACC. Cardiovascular imaging · 2015Trial
- Trial
- Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial.European journal of heart failure · 2015Trial
- Survival and outcomes of coronary artery bypass grafting in patients with extremely low ejection fraction (≤20%): A systematic review and meta-analysis.JTCVS open · 2026Article
- Korean Society of Interventional Cardiology Expert Consensus for the Management of Chronic Coronary Syndrome: Part 2.Korean circulation journal · 2026Review
- Mechanical Circulatory Support on Coronary Artery Bypass Grafting for Advanced Ischemic Cardiomyopathy: State of the Art.Medicina (Kaunas, Lithuania) · 2026Review
- The Role of Myocardial Revascularization in Ischemic Heart Failure in the Era of Modern Optimal Medical Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- Optimizing Revascularization in Ischemic Cardiomyopathy: Comparative Evidence on the Benefits and Indications of CABG and PCI.Life (Basel, Switzerland) · 2025Review
- Do patients with ischaemic cardiomyopathy benefit from off-pump coronary bypass surgery? (From the KROK registry).Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Impact of preoperative anemia in ischemic cardiomyopathy with or without coronary artery bypass grafting.Journal of thoracic disease · 2025Article
- Analysis of risk factors and development of a prediction model for long-term prognosis in patients with ischemic heart failure after percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2025Article
- Does Cardiac Function Improvement With Coronary Artery Bypass Grafting Reduce All-Cause Mortality?Annals of thoracic surgery short reports · 2024Article
- Current indications and surgical strategies for myocardial revascularization in patients with left ventricular dysfunction: a scoping review.Journal of cardiothoracic surgery · 2024Article
- Myocardial Recovery in Cardiogenic Shock.Methodist DeBakey cardiovascular journal · 2024Review
- Percutaneous Coronary Intervention for Heart Failure: Worth the Cost?Circulation. Cardiovascular quality and outcomes · 2024Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
18 authors at 14 institutions in 8 countries.
Funding
Abstract
backgroundPatients with ischemic left ventricular dysfunction have higher operative risk with coronary artery bypass graft surgery (CABG). However, those whose early risk is surpassed by subsequent survival benefit have not been identified.
objectivesThis study sought to examine the impact of anatomic variables associated with poor prognosis on the effect of CABG in ischemic cardiomyopathy.
methodsAll 1,212 patients in the STICH (Surgical Treatment of IsChemic Heart failure) surgical revascularization trial were included. Patients had coronary artery disease (CAD) and ejection fraction (EF) of ≤35% and were randomized to receive CABG plus medical therapy or optimal medical therapy (OMT) alone. This study focused on 3 prognostic factors: presence of 3-vessel CAD, EF below the median (27%), and end-systolic volume index (ESVI) above the median (79 ml/m(2)). Patients were categorized as having 0 to 1 or 2 to 3 of these factors.
resultsPatients with 2 to 3 prognostic factors (n = 636) had reduced mortality with CABG compared with those who received OMT (hazard ratio [HR]: 0.71; 95% confidence interval [CI]: 0.56 to 0.89; p = 0.004); CABG had no such effect in patients with 0 to 1 factor (HR: 1.08; 95% CI: 0.81 to 1.44; p = 0.591). There was a significant interaction between the number of factors and the effect of CABG on mortality (p = 0.022). Although 30-day risk with CABG was higher, a net beneficial effect of CABG relative to OMT was observed at >2 years in patients with 2 to 3 factors (HR: 0.53; 95% CI: 0.37 to 0.75; p<0.001) but not in those with 0 to 1 factor (HR: 0.88; 95% CI: 0.59 to 1.31; p = 0.535).
conclusionsPatients with more advanced ischemic cardiomyopathy receive greater benefit from CABG. This supports the indication for surgical revascularization in patients with more extensive CAD and worse myocardial dysfunction and remodeling. (Comparison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [STICH]; NCT00023595).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.